The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

The steep monthly costs of GLP-1 medications have long been a major obstacle for many patients trying to find effective ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through its LillyDirect platform.

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct platform, widening access in a fast-moving obesity market. The 2.5-mg ...

President Donald Trump announced a new agreement with Eli Lilly and Novo Nordisk to expand coverage and lower prices for popular obesity drugs Zepbound and Wegovy, part of the GLP-1 class of ...

Eli Lilly has lowered the price of its GLP-1 drug Zepbound (tirzepatide) in single-dose vials, with the starting dose now available for $299 per month through the company’s direct-to-consumer platform ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...